Site Tianjin is a strategic manufacturing site of Novo Nordisk. It supplies to both global and domestic market with durable devices for insulin injection and finished products of insulin. Site Tianjin locates in Tianjin Economic-Technological Development Area (TEDA). It covers an area of 128,000 square metres and employs approximately 1100 employees.
The site was established in 1995, expanded in TEDA in 2002 for durable devices production. At the end of 2008, it was further expanded for insulin production.
Site Tianjin has become the single durable devices supplier of Novo Nordisk and the biggest production site outside Denmark for insulin formulation and filling.
